




PINNACLE
LIFESCIENCE

Subsidiary of  Aarti Drugs Ltd.



UNITED BY OUR GOAL TO BUILD A HEALTHIER WORLD



About Pinnacle Life Science

Pinnacle Life Science Pvt. Ltd., established in 2015, is a wholly owned subsidiary of Aarti Drugs Ltd. (ADL) and forms part of the \$1.5 billion Aarti Group of Industries. Backed by ADL's 41 years of commitment to healthcare, Pinnacle has built strong capabilities in bulk APIs, intermediates, and finished formulations, with complete vertical integration.

We take pride in our comprehensive product portfolio, covering both acute and chronic therapies, supported by a robust annual production capacity of 3 billion tablets and 300 million capsules. With a global presence spanning North America, Central and Latin America (including Brazil and Mexico), Europe, UK, the MENA region, French West Africa, East Africa, Australia, Central Asia and Southeast Asia, we serve more than 250 clients worldwide. Our two state-of-the-art, cGMP-compliant manufacturing facilities in India enable us to deliver high-quality products across multiple therapeutic segments including anti-diabetic, anti-cancer, anti-bacterials, anti-protozoal, anti-fungal, anti-allergic, anti-hypertensive, anthelmintics, gastrointestinal and analgesics.

In addition, Pinnacle has a dedicated oncology facility capable of handling highly potent molecules up to OEB Level-5, which has been approved by the USFDA, ANVISA, EU GMP and PIC/S Ukraine.



Our Business Models Include



Out licensing of Dossiers & commercial supply



Co-development and product launch



Potent molecules development and supply




Technology transfer project



Contract Manufacturing services


Product List- Oncology (US-FDA, ANVISA, EU GMP Approved Facility)

Sr.No	Product	Strength	Dosage form	Dossier Readiness + BE Studies
1	Abiraterone Acetate	250/500 mg	Tablets	Available
2	Dasatinib	20/50/70/80/100/140 mg	Tablets	Available
3	Imatinib	100/400 mg	Tablets	Available
4	Lenalidomide	2.5/5/10/15/20/25 mg	Capsules	Available
5	Bicalutamide	50 mg	Tablets	Available
7	Ruxolitinib	5/10/15/20/25 mg	Tablets	Available
8	Palbociclib	75/100/125 mg	Tablets	Available
6	Ibrutinib	140/280/420/560 mg	Tablets	Q3 2026
9	Everolimus ODT	2/3/5 mg	Tablets	Q4 2026
10	Nilotinib	50/150/200 mg	Capsules	Q2 2027
11	Palbociclib	75/100/125 mg	Capsules	Q3 2027
12	Lenvatinib	4/10 mg	Capsules	Q2 2027
13	Olaparib	100/150 mg	Tablets	Q1 2027
14	Axitinib	1/3/5 mg	Tablets	Q3 2027
15	Enzalutamide	40/80mg /120mg/160 mg	Tablets	Q2 2027
16	Ibrutinib	140 mg	Capsules	Q2 2027
17	Pazopanib	200/400 mg	Tablets	Q3 2027
18	Sunitinib	12.5/25/37.5/50 mg	Capsules	Q3 2027
19	Apalutamide	60/240 mg	Tablets	Q3 2027
20	Regorafenib	40 mg	Tablets	Q3 2027



Product List- Oncology (US-FDA, ANVISA, EU GMP Approved Facility)

Sr.No	Product	Strength	Dosage form	Dossier Readiness + BE Studies
21	Cabozantinib	20/40/60mg	Tablets	Q3 2027
22	Venetoclax	10/50/100mg	Tablets	Q1 2027
23	Abemaciclib	50/100/150/200mg	Tablets	Q4 2027
24	Ribociclib	200mg	Tablets	Q4 2027
25	Osimertinib	40/80mg	Tablets	Q4 2027
26	Pirtobrutinib	50/100mg	Tablets	Q4 2027



Regulated Markets Product List (UK-MHRA, EU-GMP and PIC/S approved facility)

Sr.No	Product	Strength	Dosage form	Dossier Readiness + BE Studies
1	Apixaban	2.5/5 mg	Tablets	Available
2	Celecoxib	100/200 mg	Capsules	Available
3	Zolpidem	5/10 mg	Tablets	Available
4	Sitagliptin Hydrochloride	25/50/100 mg	Tablets	Available
5	Clopidogrel	75 mg	Tablet	Available
6	Dapagliflozin	5/10 mg	Tablets	Available
7	Rivaroxaban	2.5/10/15/20 mg	Tablets	Available
8	Sitagliptin Phosphate	25/50/100 mg	Tablets	Available
9	Sitagliptin Phosphate + Metformin IR	50 mg + 500 mg 50 mg + 850 mg 50mg + 1000 mg	Tablets	Available
10	Ticagrelor	60/90 mg	Tablets	Available
11	Vildagliptin	50 mg	Tablet	Available
12	Aripiprazole	10 mg, 15 mg	Tablet	Available
13	Atorvastatin	10 mg, 20 mg, 40 mg	Tablet	Available
14	Azithromycin	500 mg	Tablet	Available
15	Carvedilol	25 mg, 12.5 mg, 6.25 mg	Tablet	Available
16	Ciprofloxacin	500 mg	Tablet	Available
17	Dabigatran	75/110/150 mg	Tablets	Available
18	Desloratadine	5 mg	Tablet	Available
19	Escitalopram	10 mg, 20 mg	Tablet	Available
20	Esomeprazole	20 mg, 40 mg	Capsule	Available
21	Furosemide	40 mg	Tablet	Available
22	Ibuprofen	200 mg, 400 mg, 600 mg	Tablet	Available

Regulated Markets Product List (UK-MHRA, EU-GMP and PIC/S approved facility)

Sr.No	Product	Strength	Dosage form	Dossier Readiness + BE Studies
23	Losartan	50 mg	Tablet	Available
24	Metformin IR	850 mg	IR Tablet	Available
25	Metronidazole	500 mg	Tablet	Available
26	Paracetamol	500 mg	Tablet	Available
27	Pregabalin	75 mg, 150 mg	Capsule	Available
28	Quetiapine	100 mg & 25 mg	Tablet	Available
29	Sertraline	50 mg	Tablet	Available
30	Tranexamic Acid	500 mg	Tablet	Available
31	Famotidine	10/20/40 mg	Tablet	Available
32	Metformin XR	500/750/1000 mg	Tablets	Available
33	Sitagliptin Phosphate + Metformin XR	50 mg + 500 mg / 50 mg + 1000 mg / 100 mg + 1000 mg	Tablets	Available
34	Empagliflozin	10 / 25 mg	Tablets	Available
35	Levetiracetam	500 mg, 1000 mg	Tablet	Available
36	Risperidone	1 mg / 3 mg	Tablet	Available
37	Dapagliflozin+ Metformin IR	5 mg + 850 mg / 5 mg + 1000 mg	Tablets	Available
38	Tadalafil	2.5 / 10 / 15 / 20 mg	Tablets	Available
39	Vildagliptin + Metformin	50 mg + 850 mg 50 mg + 1000 mg	Tablets	Available
40	Prochlorperazine	5 mg	Tablets	Q4 2026
41	Perindopril + Amlodipine	5 mg + 5 mg / 5 mg + 10 mg / 10 mg + 5 mg / 10 mg + 10 mg	Tablets	Q3 2026
42	Linagliptin	5 mg	Tablets	Q3 2026

Regulated Markets Product List (UK-MHRA, EU-GMP and PIC/S approved facility)

Sr.No	Product	Strength	Dosage form	Dossier Readiness + BE Studies
43	Acamprosate	333 mg	Tablet	Q4 2026
44	Clobazam	10 mg	Tablets	Q2 2027
45	Clonazepam	2mg, 0.5mg	Tablet	Q2 2027
46	Apixaban	1 mg / 1 ml	Oral solution	Q4 2027
47	Sulfasalazine	500 mg	EC Tablet	Q2 2027
48	Dapagliflozin + Metformin XR	5 mg + 500 mg/ 10 mg + 500 mg/ 5 mg + 1000 mg/ 10 mg + 1000 mg	Tablets	Q2 2027
49	Emagliflozin +Linagliptin	10 mg + 5 mg/ 25 mg + 5 mg	Tablets	Q2 2027
50	Linagliptin + Metformin	2.5 mg + 850 mg 2.5 mg + 1000 mg	Tablets	Q3 2027
51	Mirabegron PR	25/50 mg	Tablets	Q2 2027
52	Azathioprine	50/75/100 mg	Tablets	Q3 2027
53	Budesonide	3 mg	Capsules	Q2 2027
54	Leflunomide	10 mg	Tablet	Q2 2027
55	Empagliflozin + Metformin	2.5 mg + 1000 mg / 12.5 mg + 850 mg / 5 mg + 1000 mg / 5 mg + 850 mg /	Tablets	Q1 2027

Oncology Facility




Approvals





Global Presence




Group of Companies



Get in touch: export.pinnacle@aartidrugs.com



Brochure



Website

Corporate office:

Pinnacle Life science, 3rd Floor, Mahendra Industrial Estate, Plot No. 109 D,
Road Number 29, Sion Cir, Mumbai - 400022, India. +(91) - (22) - 24019025